Literature DB >> 3907188

Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

G A Prince, V G Hemming, R L Horswood, R M Chanock.   

Abstract

Human convalescent antiserum to respiratory syncytial virus (RSV) administered intraperitoneally to cotton rats prior to RSV challenge provided near-complete protection from pulmonary infection. Antiserum given subsequent to viral challenge reduced pulmonary viral titers 100-fold or greater within 24 h. Sandoglobulin, a preparation of purified human IgG with high titer of anti-RSV neutralizing activity, produced the same effects as convalescent antiserum. Sandoglobulin was absorbed rapidly and produced a significant therapeutic reduction in virus titer within 3 h. The level of virus reduction in pulmonary and nasal tissues was directly proportional to the neutralizing antibody titer in the cotton rat serum, and was always greater in the lungs than the nose. Animals treated therapeutically with Sandoglobulin had a depressed primary antibody response to infection, but were completely resistant to reinfection with RSV. Histologic examination of pulmonary tissues from Sandoglobulin-treated animals showed no pathologic changes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3907188     DOI: 10.1016/0168-1702(85)90045-0

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  73 in total

Review 1.  Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases.

Authors:  V G Hemming
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 2.  Current research on respiratory viral infections: Third International Symposium.

Authors:  A C Schmidt; R B Couch; G J Galasso; F G Hayden; J Mills; B R Murphy; R M Chanock
Journal:  Antiviral Res       Date:  2001-06       Impact factor: 5.970

3.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

4.  In Memoriam: Robert M. Chanock, MD, 1924–2010.

Authors:  Albert Z Kapikian; David M Morens; Anthony S Fauci
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

5.  The role of maternal antibodies in the emergence of severe disease as a result of fragmentation.

Authors:  David Fouchet; Stéphane Marchandeau; Nargès Bahi-Jaber; Dominique Pontier
Journal:  J R Soc Interface       Date:  2007-06-22       Impact factor: 4.118

6. 

Authors:  François Freymuth; Geneviève Eugène; Jacques Brouard; Astrid Vabret; Joëlle Petitjean; Françoise Bonnin
Journal:  Ann Inst Pasteur Actual       Date:  2000-04-05

7.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity.

Authors:  John V Williams; Sharon J Tollefson; Joyce E Johnson; James E Crowe
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 9.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

10.  Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses.

Authors:  Richard Singleton; Nathalie Etchart; Sam Hou; Lisa Hyland
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.